International Journal of Biological Sciences (ISSN: 1449-2288, E-ISSN: 1449-2288) is a premier open-access journal published by IVYSPRING INTERNATIONAL PUBLISHING since 2005, located in Australia. With a commitment to advancing knowledge in the life sciences, this journal covers a wide spectrum of disciplines, including Applied Microbiology and Biotechnology, Cell Biology, Developmental Biology, Ecology, Evolution, Behavior and Systematics, and Molecular Biology, earning a distinguished Q1 ranking in these fields as of 2023. It stands out with exceptional Scopus rankings, placing in the top ranks across multiple categories, such as the 98th percentile in Ecology, Evolution, Behavior and Systematics and the 94th percentile in Applied Microbiology and Biotechnology. The journal fosters an open access philosophy, ensuring that research findings are readily available to the scientific community and the public, and invites original research articles, reviews, and commentaries. With its mission to disseminate high-quality research, the International Journal of Biological Sciences serves as an essential resource for researchers, professionals, and students seeking to deepen their understanding and drive innovation in biological sciences.

CELL CYCLE, an esteemed journal published by Taylor & Francis Inc., stands at the forefront of biological research, focusing on the intricate mechanisms of cell proliferation, molecular biology, and developmental biology. With an ISSN of 1538-4101 and an E-ISSN of 1551-4005, this journal has established its influence in the field with a commendable impact factor reflecting its rigorous peer-review process and high-quality publications. Notably, in 2023, it achieved a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in both Cell Biology and Developmental Biology, marking its vital role in advancing scientific understanding and innovation. Operating within a converged framework from 2002 to 2024, CELL CYCLE caters to a diverse audience of researchers, professionals, and students eager to explore contemporary findings and emerging trends. The journal's objective is to disseminate groundbreaking research that enhances our understanding of cellular mechanisms, fostering collaboration and innovation. Although not an open-access journal, it remains a premier source for those engaged in cell cycle research, and its contributions have significant implications for fields such as healthcare, biotechnology, and genetics.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

CELLULAR SIGNALLING, published by Elsevier Science Inc, is a premier journal within the realm of Cell Biology, boasting an impressive Q2 category ranking as of 2023. With an ISSN of 0898-6568 and an E-ISSN of 1873-3913, the journal has established itself as a critical platform for advancing the understanding of cellular mechanisms and signal transduction pathways since its inception in 1989. Covering a vast array of topics in Biochemistry, Genetics, and Molecular Biology, it ranks notably at 87 out of 285 in the Scopus list, placing it in the 69th percentile among its peers. The journal serves as an invaluable resource for researchers, professionals, and students seeking high-quality, impactful studies that drive forward the field of cellular biology. While it operates under traditional subscription access, its highlights include rigorous peer-reviewed articles, reviews, and insights that continue to shape current scientific discourse.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Cancer Biotherapy and Radiopharmaceuticals, an esteemed publication by Mary Ann Liebert, Inc., is a premier journal in the field of oncology that addresses the evolving landscape of cancer treatment through innovative biotherapeutics and radiopharmaceutical interventions. With an ISSN of 1084-9785 and an E-ISSN of 1557-8852, this journal provides a vital platform for researchers, clinicians, and industry experts to share cutting-edge findings and methodologies that shape cancer therapeutic practices. Its impressive impact factor and Scopus ranks highlight its significant contribution to the field, particularly within the categories of Oncology and Radiology, where it consistently secures a position in the upper quartiles. As an open access journal, it enables free dissemination of knowledge, ensuring accessibility for a global audience. By focusing on clinical applications, experimental research, and the latest technological advancements, Cancer Biotherapy and Radiopharmaceuticals serves not only as a repository of knowledge but also as a catalyst for future research and development in cancer therapy, making it an invaluable resource for the academic community and healthcare professionals alike.